NEW MOLECULAR AND NEUROINFLAMMATORY BIOMARKERS FOR PRECLINICAL DIAGNOSIS OF NEURODEGENERATIVE DISEASES

Abstract

Nonrodegenerative diseases represent such a geterogenous group with a chronic progression of the central nervous system, characterizing the pre-clinical period and pre-clinical manifestation, which effectively restricts the possibilities of timely diagnosis and evaluative treatments. In the meantime, the presentation of pathogeneese data is published in the public domain, indicating that the key role of the pathological aggregation of Belkov, neyrovospalenia, activations of glialn pengamh cell and dysregulation of immunn wawamh mechanism, forming the basis of the nerodegenerative process, will be extended to the occurrence of clinical symptomatology. The review analyzes modern domestic and foreign studies on molecular and neuroinflammatory biomarkers used and being developed for preclinical diagnosis of neurodegenerative diseases. The amyloid, tau, and synuclein-associated markers, as well as cytokine and glial parameters reflecting various links in the neuroinflammatory response, were considered. Special attention is paid to the biomarker of spin-and-spin tests and how to make a good use of the tool in the early days of the undeclared neorodegenerative process, monitoring and evaluation of therapeutic responses. It is shown that there is no significant potential of the specificity of the specificity, the variability of the specificity, the variability of the specificity and the variability of the uniformity of the specificity of the specificity, the variability of the specificity of the specificity, the variability of the specificity of the specificity and the absence of the uniformity of the diagnostics of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the specificity of the patient. There is a need for integration of biomarkern wawrabh data with clinical and non-performance evaluative evaluative indicators, and the large-scale-longitudn wawrabh is being investigated for sub-determinations and prognostic meanings. Representativeservice data; testify about the prospects of biomarker-specific approach for formations personalised; strategy and early diagnosis; and the patient with nerodegenerative diseases;